Sanofi India Ltd Share Price (SANOFI)

Sanofi India to Pay Dividend of Rs 117.00 - 12 Apr, 2024

Sanofi India (NSE:SANOFI) announces a dividend payout of Rs 117.00, with a yield of 2%. EPS is expected to grow by 31.4% in the next year. The company's dividend history has been unstable, but dividends have grown rapidly.

Sanofi India Ltd Up 1.15% on NSE - 04 Apr, 2024

Sanofi India Ltd stock is up 1.15% on the NSE, trading at Rs 8742.2 as of 12:49 IST. The stock has gained 49.22% in the last year compared to a 28.03% gain in NIFTY and a 56.77% gain in the Nifty Pharma index. The PE ratio based on TTM earnings ending December 23 is 31.66.

Sanofi India Ltd Stock Up 0.46% on NSE - 01 Apr, 2024

Sanofi India Ltd stock is up 0.46% on the NSE, trading at Rs 8151.5 as of 12:44 IST. The stock has gained 40.71% in the last year compared to a 29.18% gain in NIFTY and a 58.96% gain in the Nifty Pharma.

Sanofi India to Pay Dividend of ₹117.00 per Share - 29 Mar, 2024

Sanofi India Limited will pay a dividend of ₹117.00 per share on June 13, which is above the industry average and represents 2.1% of the current stock price. While earnings are expected to expand by 31.4%, the last payment made up 196% of cash flows, indicating that the company may be more focused on returning cash flow to shareholders than retaining it for future growth.

Cipla Partners with Sanofi India for CNS Product Range Distribution - 27 Mar, 2024

Sanofi India has signed an exclusive partnership with Cipla for the distribution and promotion of its Central Nervous System (CNS) product range, including six brands such as Frisium®, a leading anti-epileptic drug. Cipla will handle the distribution of these products in India.

Sanofi India Partners with Cipla for CNS Product Line Distribution - 26 Mar, 2024

Sanofi India has entered into an exclusive distribution and marketing partnership with Cipla Limited to expand the reach of its Central Nervous System (CNS) product line in India. As part of this collaboration, Cipla will handle the distribution of Sanofi India's six CNS brands.

Sanofi India Signs Distribution Agreement with Emcure Pharmaceuticals - 14 Mar, 2024

Sanofi India has approved an exclusive distribution and promotion agreement with Emcure Pharmaceuticals for its cardiovascular products in India. Emcure will exclusively distribute and promote Sanofi's well-established brands like Cardace, Clexane, Targocid, Lasix, and Lasilactone.